Subscription to Access Comprehensive Drug Database for NCATS

INTRODUCTION

PURSUANT TO FAR Subpart 5.2 Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT ACTION.

THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) intends to award a purchase order for subscription to access comprehensive drug database. The rationale for this sole source is exclusive licensing and continuity of science as this same database has been utilized for ongoing assays and studies and must continue to be accessible to the Government going forward for them.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE

The intended procurement is classified under NAICS code 511210, Software Publishers, with a small business size tandard of $41.5 million.

REGULATORY AUTHORITY

The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) in effect through the Federal Acquisition Circular (FAC) 2021-07 with effective date of September 10, 2021.

STATUTORY AUTHORITY

This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source.

DESCRIPTION OF REQUIREMENT

Background and Purpose
The NCATS Chemical Genomics Center (NCGC) requires subscription or other access to a comprehensive database of information regarding drugs, investigational drugs and their mechanisms of action, pathway interaction, diseases, pharmacological data, and relevant patents.

Project Description

The database must be capable of providing the following:

• Reliable, detailed information across multiple disciplines to support successful drug research and development;
• Data updated daily;
• All drug information integrated and easy-to-use to facilitate scientists making earlier, more educated decisions;
• Information of 400 Annual Conferences, 11,000 peer reviewed journals, multiple global patent offices, and 5,500 + company and research institution reports;
• Information on over 560,000 drugs and biologics;
• Information on over 44,000 genes and targets;
• Information on over 41,000 biomarkers;
• Information on over 2.9 million biomarker uses;
• Information on over 99,000 experimental models;
• Information on over 430,000 patents;
• Information on over 2.5 million pharmacology data points;
• Information on over 2.5 million articles and publications;
• Information on over 2,600 diseases;
• Information on over 30 therapeutic areas;
• Information on, but not limited to, oncology, immunology, vaccines, respiratory, rheumatology, endocrinology, cardiovascular, and the central nervous system;
• Information on over 1,200,000 safety alerts corresponding to over 23,000 drugs and biologics and more than 15,000 targets of pharmacological interest;
• Information to identify toxicology and safety signals, mitigate safety liabilities, and de-risk early-stage assets; and
• Allow for seamless integration of safety information into preclinical research, clinical trial planning, regulatory monitoring, and management strategy.
  

License Term
December 1, 2021 to November 30, 2022

Options:

Option Term One (1): December 1, 2022 to November 30, 2023
Option Term Two (2): December 1, 2023 to November 30, 2024

CLOSING STATEMENT

This synopsis is not a request for competitive proposals; however, All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.

Responses to this notice must include sufficient information to establish the interested parties' bona-fide capabilities of providing products and or services that meet the requirement. Responses that fail to include relevant technical capability information and all terms and conditions may be assessed as not capable of meeting the requirement.

The respondent must also provide their Dun & Bradstreet Number (DUNS) number, organization name, address, point-of-contact, and size and type of business (e.g., 8(a), HubZone, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by 01:00 PM Eastern Standard Time, November 17, 2021, and reference number 75N95022Q00014.
All responses must be emailed to Mark McNally, Contracting Officer, at mark.mcnally@nih.gov.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.